Company: BIAF
Filing Date: 2025-05-07
Form Type: 424B4
Source: 0001641172-25-008977
Chunk: 23

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-07
Form: 424B4
Chunk 23
---
 to them under the securities purchase agreement including (i) timely delivery of shares; (ii) agreement to not enter into variable rate transactions for 12 months from the closing of the purchase and sale of the securities in this offering (the “closing”), subject to certain exceptions; (iii) agreement to not enter into any financings for 60 days from closing; and (iv) indemnification for breach of contract. Those purchasers who do not enter into the Purchase Agreement and do not provide us with information required for registration of the shares of Common Stock to be issued upon an Anti-Dilution Adjustment shall not have any of their shares issuable as a result of an Anti-Dilution Adjustment included in the registration statement we will file covering the resale of the shares issuable as a result of an Anti-Dilution Adjustment and will not be able to effect a cashless exercise with respect to such shares.

There is no public market for the May 2025 Warrants or Pre-Funded Warrants.

There is no established public trading market for the May 2025 Warrants or Pre-Funded Warrants offered hereby, and we do not expect a market to develop. In addition, we do not intend to apply to list the May 2025 Warrants or Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of those securities will be limited.

The May 2025 Warrants in this offering are speculative in nature.

Following this offering, the market value of the May 2025 Warrants, if any, is uncertain and there can be no assurance that the market value of the May 2025 Warrants will equal or exceed their imputed public offering price. In the event that our Common Stock price does not exceed the exercise price of the May 2025 Warrants during the period when such May 2025 Warrants are exercisable, such May 2025 Warrants may not have any value. Furthermore, each May 2025 Warrant will expire five years from the effective date of Warrant Stockholder Approval.

Except as set forth in the May 2025 Warrants and Pre-Funded Warrants, Holders of the May 2025 Warrants and Pre-Funded Warrants will not have rights of holders of our shares of Common Stock until such May 2025 Warrants and Pre-Funded Warrants are exercised.

Except as set forth in the May 2025 Warrants and Pre-Funded Warrants the